[Ibopamine--pharmacologic principles]
- PMID: 1686693
[Ibopamine--pharmacologic principles]
Abstract
Ibopamine is the 3,4-diisobutyrylester of N-methyl-dopamine (epinine). Oral ibopamine is transferred during and after resorption (first-pass effect) to the active metabolite epinine by blood and tissue esterases. 200 mg ibopamine lead to maximal plasma concentrations of 60 to 100 nmol/l. The ratio of total epinine to free epinine is about 10:1. Epinine is intensively metabolized so that less than 1% of the oral dosage is eliminated via the kidneys. The plasma half-life of epinine amounts to about 45 min. Epinine activates dopamine (DA1, DA2)-, beta 1- and beta 2- as well as alpha-receptors. The affinity is of the other: DA1, DA2 greater than beta 1, beta 2 greater than alpha. Stimulation of postsynaptic DA1-receptors predominantly induces renal vasodilation and increase in diuresis. Stimulation of presynaptic DA2-receptors leads to a reduced liberation of noradrenaline (NA) from its presynaptic storage vesicles. This effects a decrease in NA-plasma concentration, peripheral resistance, and it is partly responsible for diuresis and natriuresis. Investigations in isolated organs have shown that the action on DA1, DA2-receptors occurs in the range of 100-700 nmol/l), whereas stimulation of beta 1- and beta 2-receptors affords significantly higher levels (affinity to human cardiac beta 1- and beta 2-receptors 5-10 mumol/l). alpha-receptors are only stimulated at still higher concentrations.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Pharmacological profile of ibopamine. A summary of experiments on anaesthesized dogs.Cardiology. 1990;77 Suppl 5:22-9. doi: 10.1159/000174692. Cardiology. 1990. PMID: 1980631 Review.
-
[New inotropic agents in the treatment of congestive heart failure].Rev Port Cardiol. 1993 Nov;12 Suppl 4:19-28, 7-8. Rev Port Cardiol. 1993. PMID: 7904458 Review. Portuguese.
-
Comparison of the effects of the novel inotropic agent, ibopamine, with epinine, dopamine and fenoldopam on renal vascular dopamine receptors in the anesthetized dog.J Pharmacol Exp Ther. 1987 Aug;242(2):573-8. J Pharmacol Exp Ther. 1987. PMID: 2886644
-
Efficacy of ibopamine treatment in patients with advanced heart failure: purpose of a new therapeutic scheme with multiple daily administrations.J Cardiovasc Pharmacol. 1989;14 Suppl 8:S111-7. J Cardiovasc Pharmacol. 1989. PMID: 2483436
-
Pharmacotherapeutic profile of ibopamine in heart failure.J Cardiovasc Pharmacol. 1989;14 Suppl 8:S118-23. J Cardiovasc Pharmacol. 1989. PMID: 2483437 Review.
Cited by
-
Ibopamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in congestive heart failure.Drugs Aging. 1993 Nov-Dec;3(6):556-84. doi: 10.2165/00002512-199303060-00008. Drugs Aging. 1993. PMID: 7906158 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical